Company Reports

Elanco delivered second-quarter results that included organic revenue growth and operating margins of 8% and 8.6%, respectively. The pet segment grew 11%, while the farm animal division was up 5%. Management raised its revenue and earnings-per-share outlook for the full year.

Though the firm is among the four largest animal drug producers, Elanco has faced challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been rather inconsistent. Now the firm has finally begun to realize some of its potential.

Elanco delivered first-quarter results that featured revenue of $1.37 billion, up 10% organically year over year, and operating margin expansion of roughly 220 basis points, spurring management to raise its revenue outlook by $60 million at the midpoint. Shares rose 8% intraday on May 6.

Though the firm is among the four largest animal drug producers, Elanco has faced challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been rather inconsistent. Now the firm has finally begun to realize some of its potential.

Elanco finished out a stellar 2025 with fourth-quarter revenue 9% in constant currency and adjusted net income of $64 million. Innovative products such as Credelio Quattro and Experior fueled robust full-year revenue growth of $4.7 billion.

Elanco delivered third-quarter results that included 9% organic revenue growth in constant currency, and operating margin adjusted for amortization (and divestitures) rose to 8%, up from 5% in the prior-year period.

Though the firm is among the four largest animal drug producers, Elanco faces challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been rather inconsistent. Further, Elanco’s product portfolio also poses challenges to the realization of this strategy.

Though the firm is among the four largest animal drug producers, Elanco faces challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been rather inconsistent. Further, Elanco’s product portfolio also poses challenges to the realization of this strategy.

For the second quarter, Elanco reported revenue growth of 5%, driven by companion animal health (up 10% organic) and farm animal (up 7%, adjusted for the divestiture of the aqua business).

Elanco posted a quarterly reported revenue decline of 1%, but sales adjusted for the divestiture of the aquaculture business in constant currency were up 4% year over year. Management raised guidance to reflect more favorable foreign exchange and underlying demand.

Facing stiff foreign exchange headwinds, Elanco posted a 1% reported decline in fourth-quarter revenue, though constant currency growth ran at 4% year over year. Quarterly operating margin clocked in around 1%, unchanged for the prior-year period.

Though the firm is among the four largest animal drug producers, Elanco faces challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been inconsistent. Further, Elanco’s product portfolio also poses challenges to the realization of this strategy.

Elanco posted anemic third-quarter revenue growth of 1% in constant currency, and negative operating margin adjusted for the divestiture of its aquaculture business.

Though the firm is among the four largest animal drug producers, Elanco faces challenges in evolving into a more dominant and profitable competitor. The firm’s stated strategy relies heavily on innovation to commercialize potential blockbuster therapies and feed a product pipeline that can maintain profitable growth over the long term. While we think this strategy is sound—and we have seen rival Zoetis reach impressive success with it—Elanco’s execution has been inconsistent. Further, Elanco’s product portfolio also poses challenges to the realization of this strategy.

We initiate coverage on animal health firm Elanco, which participates in both the production animal segment with feed additives, as well as companion animals drug therapies.